title: Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics.
abstract: The objective of this study was to evaluate the feasibility and outcomes of incorporating value-of-information (VOI) analysis into a stakeholder-driven research prioritization process in a US-based setting.
  
  
  
  . Within a program to prioritize comparative effectiveness research areas in cancer genomics, over a period of 7 months, we developed decision-analytic models and calculated upper-bound VOI estimates for 3 previously selected genomic tests. Thirteen stakeholders representing patient advocates, payers, test developers, regulators, policy makers, and community-based oncologists ranked the tests before and after receiving VOI results. The stakeholders were surveyed about the usefulness and impact of the VOI findings.
  
  
  
  The estimated upper-bound VOI ranged from $33 million to $2.8 billion for the 3 research areas. Seven stakeholders indicated the results modified their rankings, 9 stated VOI data were useful, and all indicated they would support its use in future prioritization processes. Some stakeholders indicated expected value of sampled information might be the preferred choice when evaluating specific
  
  
  
  Limitations. Our study was limited by the size and the potential for selection bias in the composition of the external stakeholder group, lack of a randomized design to assess effect of VOI data on rankings, and the use of expected value of perfect information v. expected value of sample information methods.
  
  
  
  Value of information analyses may have a meaningful role in research topic prioritization for comparative effectiveness research in the United States, particularly when large differences in VOI across topic areas are identified. Additional research is needed to facilitate the use of more complex value of information analyses in this setting.
authors: Department of Pharmacy, University of Washington, Seattle, Washington (JJC, RT, JR, JG, DLV)
authors: Josh J
authors: JJ
authors: Carlson
authors: Department of Pharmacy, University of Washington, Seattle, Washington (JJC, RT, JR, JG, DLV)
authors: Rahber
authors: R
authors: Thariani
authors: Department of Pharmacy, University of Washington, Seattle, Washington (JJC, RT, JR, JG, DLV)
authors: Josh
authors: J
authors: Roth
authors: Department of Pharmacy, University of Washington, Seattle, Washington (JJC, RT, JR, JG, DLV)
authors: Julie
authors: J
authors: Gralow
authors: SWOG and University of Michigan Medical School, Ann Arbor, Michigan (NLH, LB)
authors: N Lynn
authors: NL
authors: Henry
authors: Center for Medical Technology Policy, Baltimore, Maryland (LE, PD)
authors: Laura
authors: L
authors: Esmail
authors: Center for Medical Technology Policy, Baltimore, Maryland (LE, PD)
authors: Pat
authors: P
authors: Deverka
authors: Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington (SDR)
authors: Scott D
authors: SD
authors: Ramsey
authors: SWOG and University of Michigan Medical School, Ann Arbor, Michigan (NLH, LB)
authors: Laurence
authors: L
authors: Baker
authors: Department of Pharmacy, University of Washington, Seattle, Washington (JJC, RT, JR, JG, DLV)
authors: David L
authors: DL
authors: Veenstra
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D023281:Genomics; D006801:Humans; D007255:Information Services; D009369:Neoplasms / Q000235:genetics*; D012106:Research; D014481:United States
chemical_list: D014408:Biomarkers, Tumor
keywords: decision analysis; economic analysis; value of information
references: Clin Transl Sci. 2011 Jun;4(3):188-98
references: 21707950
references: Health Aff (Millwood). 2011 Dec;30(12):2259-68
references: 22147853
references: Genet Med. 2005 Jul-Aug;7(6):380-9
references: 16024969
references: Med Care. 2008 Apr;46(4):349-56
references: 18362813
references: Pharmacoeconomics. 2010;28(10):843-53
references: 20831292
references: Health Econ. 1996 Nov-Dec;5(6):513-24
references: 9003938
references: Health Econ. 2010 May;19(5):549-61
references: 19399753
references: Pharmacoeconomics. 2010;28(9):699-709
references: 20629473
references: Pharmacoeconomics. 2006;24(11):1055-68
references: 17067191
references: Med Care. 2012 May;50(5):388-93
references: 22274803
references: Med Decis Making. 2004 Mar-Apr;24(2):207-27
references: 15090106
references: Lancet. 2009 Oct 24;374(9699):1432-40
references: 19767093
references: Health Technol Assess. 2004 Jul;8(31):1-103, iii
references: 15248937
references: Value Health. 2009 Jan-Feb;12(1):20-7
references: 18647257
references: Med Decis Making. 2011 Nov-Dec;31(6):E1-E22
references: 21712493